Please complete the CAPTCHA to continue
@inex.sg
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Kane Black is listed as CEO - IKIGAI Ventures Limited (LSE:IKIV) | Director - INEX Innovate | EY Singapore Entrepreneur Of The Year 2022 - Biotechnology at Ikigai Ventures Limited (IKIV:LSE), based in Singapore. AeroLeads shows a work email signal at inex.sg and a matched LinkedIn profile for Kane Black.
Kane Black previously worked as Chief Executive Officer at Ikigai Ventures Limited (Ikiv:Lse) and Non Executive Director at Inex Innovate. Kane Black holds Bachelor Of Business Administration (Bba), Cost Accounting from Bond University.
This section adds company-level context without repeating Kane Black's masked contact details.
AeroLeads found 1 current-domain work email signal for Kane Black. Compare company email patterns before reaching out.
A seasoned technology entrepreneur with a diverse international background in senior and executive leadership roles across the technology, biotechnology, medical device, and healthcare investment sectors worldwide. Having lived in Asia for almost 20 years, a fluent Japanese speaker and now a Singapore Permanent Resident, I embarked on my professional journey with Adtec Corporation K.K., a semiconductor trading company listed on the Tokyo Stock Exchange (Jasdaq), now known as AKIBA Holdings (6840:Tokyo). During my tenure, I held the position of Director for the UK & Europe, based in Tokyo and later London. Playing a pivotal role in the acquisition of Adtec Corporation by Shinden Hightex Corporation (3131:Tokyo) in 2005, I continued serving as a Director in London.Transitioning to a private family office in Hong Kong in 2009, I specialized in healthcare investments, where we identified ground-breaking innovators and disruptors in medical technology across various sectors, including devices, diagnostics, therapeutics, and natural health products.In 2012, I co-founded Nova Satra Health Sdn. Bhd. to seize opportunities in medical technology advancements, leading to the establishment of Nova Satra Dx Pte Ltd., a molecular diagnostic developer based in Singapore, in 2014, which was later backed by Malaysian conglomerate Genting Berhad.The significant merger of Nova Satra Dx with INEX Innovations Exchange in August 2019, valued at US$72 million, resulted in the creation of INEX Innovate. During my tenure as Chief Executive of the merged entity, the team expanded from 10 members to over 50, introducing numerous cutting-edge medical diagnostic technologies and garnering multiple awards, including being ranked the second fastest growing healthcare company in Singapore and 7th in the Asia Pacific by the Financial Times. In 2020, I was honored with an invitation to join the National University of Singapore's NUS Medicine International Council as a Council Member. Furthermore, in 2022, my contributions were recognized with the Ernst & Young Singapore Entrepreneur of The Year award in the Biotechnology category.In 2024 I stood down as Chief Executive of INEX Innovate, transitioning to the Board of the company as Non-Executive Director and in April 2024 I was appointed Chief Executive Officer of London Stock Exchange listed investment company IKIGAI Ventures Limited (LSE:IKIV).I hold degrees from Bond University and Griffith University, Australia.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Ikigai Ventures Limited (LSE:IKIV), is a London Stock Exchange Main Market listed, tech-focused Special Purpose Acquisition Company (SPAC). Ikigai Ventures aims to acquire dynamic, high-growth businesses across sectors such as healthcare, finance, agriculture, mining, and artificial intelligence, prioritizing those with robust ESG (Environmental, Social, Governance) credentials.
Singapore, Sg
INEX Innovate is one of Asia’s fastest growing medical technology developers and medical laboratory operators. Spun out from the National University of Singapore (NUS), INEX is Asia’s first Women’s health technology group. Founded by maternal-fetal medicine specialists, INEX focuses on developing and commercializing molecular diagnostic technologies in the areas of fetal health and women’s oncology.INEX has a broad commercial portfolio of validated tests in prenatal health, ovarian and breast cancers along with more than 48 key patents, additionally, through its wholly owned subsidiary iGene Laboratory, INEX operates a College of American Pathologist (CAP) accredited Next Generation Sequencing (NGS) laboratory that provides diagnostic testing, contract research (CRO) and COVID-19 testing services.The company has been recognised globally with a number of accolades and awards including from Frost & Sullivan, the World Intellectual Property Organisation (WIPO), The Straits Times – Singapore’s Fastest Growing Companies, the Financial Times ranking of 500 of Asia Pacific’s Fastest Growing Companies and The Business Times KPMG Enterprise 50 awards of Singapore’s 50 most enterprising ventures.For more information please visit: www.inex.sg
Singapore, Singapore, Sg
In working towards the NUS vision to be “a leading global university shaping the future”, the University has built a strong global reputation through its research and collaborations. Across 17 faculties and schools, and 29 research institutes and centres of excellence, NUS has engaged some of the world’s most brilliant minds to look into the future — from an Asian perspective.Established in 1905, the NUS Yong Loo Lin School of Medicine is a leading medical educational and research institution in Asia. With 18 departments and two centres, the School covers a full spectrum of medical specialties. Clinical faculty also staff the National University Hospital (NUH), which is the primary training institution for the School. Together with NUH, NUS Medicine has played a profound role in shaping doctors and scientists, who will be future leaders in healthcare, academic medicine and public service in Singapore, Asia and beyond.The NUS Medicine International Council (NIC) is an exclusive network of international leaders, academics and experts who will not only address the greatest challenges of our time — in healthcare, public health policy, population studies and ground-breaking research in cancer, diabetes and other chronic diseases — but will also identify promising opportunities and innovations across multi-disciplinary areas including information technology, engineering, computing, social sciences and medicine.
PT iGene Laboratory Indonesia is a joint venture between iGene Laboratory Pte Ltd of Singapore and PT Itama Ranoraya Tbk. a publicly listed healthcare company on the Indonesia Stock Exchange (IDX:IRRA)Established in 2000 PT Itama Ranoraya Tbk is engaged in hi-tech medical devices and supplies with a number of partnerships with reputable healthcare principals such as Oneject, Abbott, Terumo, HMD, BD (Becton, Dickinson and Company).
Established in 2014, iGene Laboratory Pte Ltd is a wholly owned subsidiary of INEX with a state of the art CAP accredited and Ministry of Health Licenced laboratory in Singapore's Science Park II The laboratory serves medical professionals in Singapore and the region, providing testing services based on a Whole Genome Sequencing platform.
Singapore, Singapore, Sg
Nova Satra Dx is a molecular diagnostics company headquartered in Singapore. The company is committed to empowering patients and physicians through the research, development and commercialisation of a novel blood based diagnostic test for breast cancer - EpiDx™ The test provides rapid and accurate detection of breast cancer using Asian-specific epigenetic biomarkers. Based on its clinically validated technology developed by the University of Oxford, Nova Satra’s diagnostic test detects and identify changes in gene expression which are linked to cancer.Nova Satra Dx is a Genting Group associate company.
Singapore, Singapore, Sg
Nova Satra Health is a private Malaysia based healthcare investment holding company, with the specific aim of investing in and nurturing ground breaking developments across the healthcare spectrum.
Quick answers generated from the profile data available on this page.
Kane Black works for Ikigai Ventures Limited (IKIV:LSE).
Kane Black is listed as CEO - IKIGAI Ventures Limited (LSE:IKIV) | Director - INEX Innovate | EY Singapore Entrepreneur Of The Year 2022 - Biotechnology at Ikigai Ventures Limited (IKIV:LSE).
AeroLeads has found 1 work email signal at @inex.sg for Kane Black at Ikigai Ventures Limited (IKIV:LSE).
Kane Black is based in Singapore while working with Ikigai Ventures Limited (IKIV:LSE).
Kane Black has worked for Ikigai Ventures Limited (Ikiv:Lse), Inex Innovate, Severn Capital, Nus Yong Loo Lin School Of Medicine, and Pt Igene Laboratory Indonesia.
You can use AeroLeads to view verified contact signals for Kane Black at Ikigai Ventures Limited (IKIV:LSE), including work email, phone, and LinkedIn data when available.
Kane Black holds Bachelor Of Business Administration (Bba), Cost Accounting from Bond University.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts